Baseline characteristics of patients with limited stage natural killer/T cell lymphoma.
| Characteristics | N (157) |
|---|---|
| Age | |
| Median (range) | 58 (37–78) |
| ≥60 yr (%) | 71 (45.2) |
| <60 yr (%) | 86 (54.8) |
| Sex | |
| Male (%) | 108 (68.8) |
| Female (%) | 49 (31.2) |
| Primary site | |
| Nasal cavity (%) | 117 (74.5) |
| Nasopharynx (%) | 34 (21.7) |
| Oral cavity/oropharynx (%) | 6 (3.8) |
| Ann-Arbor stage | |
| Stage I | 20 (12.7) |
| Stage II | 137 (87.3) |
| Lactate dehydrogenase | |
| ≥Upper normal limit (%) | 31 (19.7) |
| Normal (%) | 126 (80.3) |
| Ki-67 value | |
| ≥70% (%) | 25 (15.9) |
| <70% (%) | 127 (84.1) |
| B symptoms | |
| Present (%) | 40 (25.5) |
| Absent (%) | 117 (74.5) |
| ECOG performance status | |
| Grade 0–1 (%) | 114 (72.6) |
| ≥Grade 2 (%) | 43 (27.4) |
| Bulky disease (≥7.5 cm) | |
| Present (%) | 16 (10.2) |
| Absent (%) | 141 (89.8) |
| Bilateral RLN involvement | |
| Present (%) | 35 (22.3) |
| Absent (%) | 122 (87.7) |
| Therapeutic modality | |
| Chemotherapy only (%) | 81 (51.6) |
| Chemotherapy with radiotherapy (%) | 76 (48.4) |
| 18F-FDG PET/CT scan | |
| SUVmax, median (range) | 8.9 (2.7–41.0) |
Abbreviations: 18F-FDG, 18F-fluorodeoxyglucose; ASCT, autologous stem cell transplantation; ECOG, Eastern Cooperative Oncology Group; PET/CT, positron emission tomography/computed tomo-graphy; RLN, regional lymph node; SUVmax, maximum standard uptake value.
Blood Res 2021;56:72~78 https://doi.org/10.5045/br.2021.2020328
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd